The In-Office Treatment That Builds Long-Lasting Collagen
Last week, I finally decided to undergo my first in-office treatment. No, I didn't get Botox or fillers. Instead, I went with something non-invasive that promised to address my biggest concern: collagen loss.
My treatment of choice? Thermage FLX, which is FDA-approved and marketed as one of the most powerful in-office radiofrequency treatments on the market. According to one recent scientific analysis that looked at 52 surveys among dermatologists, Thermage FLX was considered 57.4% more effective than older Thermage devices. I figured that if it was good enough for Jennifer Aniston and Gwyneth Paltrow, it was good enough for me.
What is Thermage FLX?
Thermage FLX is a non-invasive monopolar radiofrequency treatment that 'ensures stimulation of endogenous collagen with just one treatment,' says Dr. Óscar Suárez, founder and medical director of Barcelona's MD Cliniques. He says it's so effective that a once-a-year treatment is enough for most people.
But what exactly makes Thermage FLX so effective? 'It's specially designed to reverse skin flaccidity and improve wrinkles and expression lines,' explains Dr. Maria Dolores Antón, an aesthetic doctor and the medical director of Antón Clinic in Valencia, Spain. 'It tightens and firms the skin through an extremely precise delivery of energy. The device can be used to treat all areas that show the effects of flaccidity: cheeks, eyelids, jawline, bags, buttocks, arms, abdomen, knees, and thighs.'
How does Thermage FLX work?
Basically, Thermage FLX emits low-frequency electromagnetic waves to generate heat below the surface of the skin. 'The heat penetrates deep into the skin to stimulate the production of collagen, which is responsible for tissue tightening, rejuvenation, and improved elasticity,' explains board certified dermatologist Dr. Tanya Kormeili, a clinical instructor at UCLA. 'Because collagen and elastin are essential for skin firmness and youthfulness, the more you build the more youthful your skin can be in theory,' she says.
Thermage FLX heats the deepest layer of the skin to around 140°F to stimulate the fibroblast to increase collagen production. 'Thermage FLX acts directly on the deep dermis in a very specific way: It causes shrinkage of old collagen and gives a message to the fibroblast to generate new, high-quality collagen,' Anton says.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories
The STD Diagnostic Market is projected to reach $17.93 billion by 2033, growing from $9.82 billion in 2024 at a CAGR of 6.92% during 2025-2033. Key growth drivers include increased STD prevalence, technological advancements in diagnostics, and enhanced accessibility to healthcare. Government initiatives and improved public awareness also bolster the market. Segments analyzed include products, testing types, and global regions, emphasizing the demand for point-of-care testing and at-home kits. Significant developments and challenges such as social stigma and regulatory hurdles are explored. Leading industry players include Siemens Healthineers, Abbott, and F. Hoffmann-La Roche. STD Diagnostic Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "STD Diagnostic Market - Testing Technologies & Forecast 2025-2033" report has been added to Diagnostic Market is expected to reach US$ 17.93 billion by 2033 from US$ 9.82 billion in 2024, with a CAGR of 6.92% from 2025 to 2033 Increased STD prevalence, public education, government campaigns, improved healthcare facilities, technological advancements in diagnostic equipment, growing need for point-of-care testing, increasing access to healthcare services, and enhanced screening among high-risk populations are the key drivers of the STD diagnostics market. The STD diagnostic market is growing considerably because of many significant factors. There is greater demand for early and accurate diagnosis because STDs are on the rise globally. Systematic testing is being promoted and public awareness is being enhanced through government programs, awareness campaigns, and education programs. Detection accuracy and speed are enhanced by advances in diagnostic technology, including molecular diagnostics and rapid point-of-care testing. Markets are supported by increased access to and infrastructure for healthcare, especially in developing countries. The expansion of the market and the growth of innovation are further supported by the increasing high-risk populations, wider acceptance of in-home testing kits, and the use of digital health solutions for Drivers for the STD Diagnostic Market Developments in diagnostic technologiesThe market is growing due to developments in diagnostic technologies that have significantly enhanced the accessibility, efficiency, and accuracy of sexually transmitted disease (STD) detection. Rapid diagnostic tests, home testing kits, and nucleic acid amplification tests have all revolutionized STD diagnosis by providing convenient and efficient testing choices. These are beneficial in distant or remote areas with poor medical services accessibility. Investments in advanced diagnostic devices have grown with the increased requirement for precise and early detection methods. In June 2023, a spinout company from the University of Birmingham, Linear Diagnostics, was funded to develop a rapid STI test, the UK National Institute for Health and Care Research (NIHR) reported. In reaction to the urgent need for faster and simpler STI diagnosis, the company is working on a 20-minute test to diagnose gonorrhea and chlamydia. The market is growing due to these technical developments that are enhancing early detection efforts and enhanced patient activities and raising awarenessGovernment actions and growing awareness are the major drivers of the STD diagnostics market growth. STIs are on the rise in many parts of the world, says recent research. WHO Member States had a target in 2022 to reduce the annual syphilis cases from 7.1 million to 0.71 million by 2030, a reduction of ten times. However, in 2022, 8 million new syphilis infections were reported among individuals aged between 15 and 49 years, up by over 1 million. The greatest increases were in the Americas and Africa. The necessity of reducing STI rates globally while ensuring that all people have access to prevention, care, and treatment has highly contributed to the demand for better and more accessible testing tools. The CDC's "Get Yourself Tested" program has also been essential in encouraging regular STD screening, among high-risk populations, and increasing awareness of the importance of early diagnosis. These markets are being fueled by a growing number of government-sponsored programs to inform the public and boost demand for STD screening services. The market will be fueled by increased focus on treatment and prevention and on regular incidence of sexually transmitted diseasesOne of the primary driving forces for the necessity for improved diagnostic testing is the growing trend of sexually transmitted illnesses (STIs) globally. Rising infection numbers are brought about by several factors, including numerous sexual partners, unsafe sex, and not knowing the prevention techniques. An estimated one million people contract a STI daily according to the World Health Organization. One of the four primary STIs - trichomoniasis, syphilis, gonorrhea, or chlamydia - infects approximately 500 million individuals a year. The urgency of accurate and timely diagnosis treatments is brought out by the increasing prevalence of these diseases. Governments and healthcare organizations are also funding STI screening programs, which is also expected to grow demand for rapid and accurate diagnosis methods. Advances in self-testing kits, point-of-care testing, and molecular diagnostics have significantly contributed to market growth. Improving early detection, treatment results, and infection control measures has been high on the agenda of healthcare in the STD Diagnostic Market Social Stigma and Privacy ConcernsThe market for STD testing is severely hampered by social stigma and privacy issues. Underdiagnosis and untreated infections result from people avoiding testing out of fear of being judged, discriminated against, or having their privacy violated. This stigma is frequently a result of societal, religious, or cultural traditions that have a negative perception of STDs. People are deterred from getting tested at clinics or medical institutions by privacy concerns over sensitive health information. Consequently, there may be less demand for STD testing, especially in conservative or low-income areas. Increased knowledge, private testing choices, and the provision of discrete at-home testing kits are necessary to remove these obstacles and promote broader adoption and HurdlesThe market for STD diagnostics is severely hampered by regulatory barriers, which postpone the approval and introduction of novel diagnostic procedures. The licensing procedure is complicated and time-consuming for producers because different nations have different and frequently strict regulatory standards. Adherence to safety assessments, clinical validation, and quality standards necessitates significant financial outlays, which can be especially taxing for smaller businesses. The market's growth is slowed by these delays, which restrict the supply of quick and creative diagnostic options. Furthermore, regionally disparate restrictions make it more difficult to enter international markets, raise prices, and prevent the broad use of cutting-edge STD detection tools. Recent Developments in STD Diagnostic Industry BioLytical Laboratories Inc. declared in March 2025 that its INSTI HIV-1/2 Syphilis Test would be available in Australia. In just 60 seconds, this dual HIV-syphilis test yields results, allowing medical providers to promptly diagnose HIV and syphilis and link patients to care. OraSure Technologies, Inc. reported in January 2025 that the FDA's Center for Biologics Evaluation and Research (CBER) had authorized a labeling update for the OraQuick HIV Self-Test. In contrast to its earlier approval for adults aged 17 and above, this update expands the age range of those eligible for the test to include adolescents aged 14 and above. The goal of this modification is to increase younger people's access to HIV testing. Key Players Analysis | Company Overview, Key Persons, Recent Development & Strategies, SWOT Analysis, Sales Analysis Siemens Healthineers AG Abbott MedMira Inc QIAGEN Danaher Corporation (Cephied) F. Hoffmann-La Roche Ltd Diasorin SpA BioMeriuex Hologic Inc. Bio-Rad Laboratories Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $9.82 Billion Forecasted Market Value (USD) by 2033 $17.93 Billion Compound Annual Growth Rate 6.9% Regions Covered Global Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. STD Diagnostic Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product6.2 By Type6.3 By Point of Testing6.4 By Countries7. Product7.1 Consumables7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Instruments & Services7.3 Software8. Type8.1 Chlamydia Testing8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Gonorrhea Testing8.3 Herpes Simplex Virus Testing8.4 Human Papilloma Virus Testing8.5 Human Immunodeficiency Virus Testing8.6 Chancroid Testing8.7 Others9. Location of Testing9.1 Laboratory Testing9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Point of Care Testing10. Countries10.1 Market Analysis10.2 Market Size & Forecast11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Siemens Healthineers AG14.2 Abbott14.3 MedMira Inc14.4 QIAGEN14.5 Danaher Corporation (Cephied)14.6 F. Hoffmann-La Roche Ltd14.7 Diasorin SpA14.8 BioMeriuex14.9 Hologic Inc.14.10 Bio-Rad Laboratories Inc.15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment STD Diagnostic Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
11 minutes ago
- Yahoo
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug. Under the agreement, Kumquat will be responsible for initiating and completing a phase-Ia study into the drug, a KRAS G12D inhibitor, while Bayer will complete development and commercial activities. Bayer said the deal complements its precision oncology development portfolio in the areas of pancreatic, colorectal and lung cancer. KRAS mutations occur in nearly 25% of human cancers, with the variant targeted by Kumquat's experimental drug still lacking effective treatment options, according to a company statement. Bayer said it has agreed to pay Kumquat up to $1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat, which since its launch in 2019 has also signed agreements with Eli Lilly and Takeda, retains an exclusive option to negotiate for participating in profit-loss sharing in the United States under the deal with Bayer. "This collaboration provides Kumquat the financial resources to accelerate its broader clinical pipeline for long-term value," Kumquat CEO Yi Liu said in a statement shared by Bayer. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies
Key market opportunities for vitiligo treatment include a shift toward personalized therapies addressing immune dysregulation, increasing awareness and early diagnosis, and innovative technologies such as JAK inhibitors, phototherapy advancements, and AI diagnostics. The sector benefits from rising demand for aesthetic solutions and holistic, patient-centric care approaches. Vitiligo Treatment Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment - Global Strategic Business Report" has been added to global market for Vitiligo Treatment was estimated at US$1.5 Billion in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Vitiligo Treatment market. The growth in the vitiligo treatment market is being propelled by a combination of medical, economic, and societal factors that are reshaping both patient demand and therapeutic innovation. One of the key drivers is the increasing prevalence of vitiligo globally, with estimates suggesting that it affects up to two percent of the population. Improved awareness and earlier diagnosis are leading more individuals to seek treatment, which is expanding the patient base and creating new market opportunities. Advances in immunology and dermatological research are encouraging pharmaceutical companies to invest in the development of novel therapies, particularly targeted treatments like JAK inhibitors and stem cell-based solutions. Regulatory agencies are also playing a supportive role by granting designations such as orphan drug status to vitiligo treatments, thereby incentivizing innovation and accelerating clinical development. The rising demand for aesthetic solutions, fueled by social media and the growing emphasis on personal appearance, is further boosting interest in effective vitiligo therapies. In parallel, the wellness movement and a broader cultural shift toward embracing diversity and skin positivity are influencing how the condition is perceived and managed. Health insurers and governments are beginning to acknowledge the psychological burden of vitiligo, leading to expanded coverage for certain treatments and increased funding for research. Technological advancements in digital health, including telemedicine and AI-powered diagnostics, are making treatment more accessible, especially in remote or underserved regions. Partnerships between pharmaceutical companies, dermatology clinics, and advocacy organizations are also helping to raise public awareness and reduce stigma. Together, these interconnected trends are creating a dynamic and optimistic outlook for the vitiligo treatment market, one that prioritizes innovation, accessibility, and comprehensive care. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bausch Health Companies Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Segmental Vitiligo segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of a 6.3%. The Non-Segmental Vitiligo segment is also set to grow at 3.4% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $412.6 Million in 2024, and China, forecasted to grow at an impressive 8.6% CAGR to reach $417.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Scope Of Study: Type (Segmental Vitiligo, Non-Segmental Vitiligo) Vitiligo Treatment (Therapy Treatment, Surgical Treatment, Medication Treatment) End-Use (Hospitals End-Use, Ambulatory Clinics End-Use, Other End-Uses) Key Attributes: Report Attribute Details No. of Pages 377 Forecast Period 2024 - 2030 Estimated Market Value in 2024 1.5 Billion Forecasted Market Value by 2030 2.1 Billion Compound Annual Growth Rate 5.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Vitiligo Treatment - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of Skin Health Throws the Spotlight on Unmet Needs in Vitiligo Treatment Increased Psychological and Social Impact of Vitiligo Drives Demand for More Effective Therapies Here's the Story How Advances in Autoimmune Research Are Unlocking New Therapeutic Pathways Emergence of Janus Kinase Inhibitors Propels Innovation in Topical and Systemic Treatment Options Growing Focus on Personalized Dermatology Supports Development of Tailored Vitiligo Interventions Here's How Phototherapy Advancements Are Enhancing Treatment Efficacy and Accessibility Rising Interest in Melanocyte Regeneration Boosts Research in Cell-Based and Stem Cell Therapies Cosmetic Industry Collaboration Expands Availability of Camouflage Products and Adjunctive Care Expansion of Dermatology Telehealth Platforms Improves Access to Diagnosis and Long-Term Management Clinical Trials in Underrepresented Populations Address Gaps in Ethnic Skin Treatment Data Growing Consumer Demand for Non-Steroidal Alternatives Encourages Natural and Herbal Product Innovation Shift Toward Holistic and Multimodal Care Models Reinforces the Value of Integrative Vitiligo Treatment Approaches FOCUS ON SELECT PLAYERS AbbVie Inc. Amgen Inc. Astellas Pharma Inc. Aurobindo Pharma Ltd. Bausch Health Companies Inc. Bristol Myers Squibb Dermavant Sciences Dr. Reddy`s Laboratories Encore Dermatology Inc. Ferrer Internacional S.A. Glenmark Pharmaceuticals Ltd. Incyte Corporation Kamada Ltd. LEO Pharma A/S Medimetriks Pharmaceuticals Pfizer Inc. Sanofi Strata Skin Sciences Sun Pharmaceutical Industries Teva Pharmaceutical Industries For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Vitiligo Treatment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data